Product Description: BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 is efficacious in a mouse allergic eosinophilic lung inflammation model[1].
Applications: COVID-19-immunoregulation
Formula: C26H19Cl2N5O4
References: [1]Watterson SH, et al. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure-activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotinic acid (BMS-688521). J Med Chem. 2010 May 13;53(9):3814-30.
CAS Number: 893397-44-9
Molecular Weight: 536.37
Compound Purity: 98.62
Research Area: Inflammation/Immunology
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Integrin
Deutsch
English
